Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

StatusNot Yet Recruiting
PhaseNot applicable
Started2024-10-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 1, 2024 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2024-09-26
minor
Study Status, Conditions v1
Re-verified, no change to tracked fields
2024-09-26
minor
Original filing
Oral Melatonin is a commercially available product available alone and as a constituent in a number of supplements. Previous research suggests that short-term supplementation with oral melatonin may amplify the recovery response to damaging resistance exercise via modulation of subsequent immune and inflammatory responses. However the effects of oral melatonin on neutrophil and monocyte invasion/migration, a critical step in the resolution of skeletal muscle tissue homeostasis, has not been examined. An oral melatonin supplement (5mg) will be provided three times daily beginning 24-hours before and ending 48-hours after an acute bout of damaging resistance exercise (total 15mg/day for 3 days). Goals: 1. To investigate the effect of melatonin on systemic and cellular responses following an acute bout of damaging resistance exercise. 2. To investigate the effect of melatonin on measures of functional performance before and during recovery from an acute bout of damaging resistance exercise.
Trial Details
NCT Number NCT06617351
Lead Sponsor University of Central Florida
Conditions Cell Migration, Cell Invasion, Exercise Recovery
Enrollment 24 participants
Start Date 2024-10-01
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01